St. Petersburg, Russia
Novartis broke ground in June of 2011 on a pharmaceutical manufacturing plant in St. Petersburg, Russia. Part of a five-year, $500 million investment, the facility will utilize advanced technologies to produce innovative therapeutics and generics. Completion is expected in 2014.